biostudies-literatureUnknown34Lopardo G<h4>Background</h4>passive immunotherapy is a therapeutic alternative for patients with COVID-19. Equine polyclonal antibodies (EpAbs) could represent a source of scalable neutralizing antibodies against SARS-CoV-2.<h4>Methods</h4>we conducted a double-blind, randomized, placebo-controlled trial to assess efficacy and safety of EpAbs (INM005) in hospitalized adult patients with moderate and severe COVID-19 pneumonia in 19 hospitals of Argentina. Primary endpoint was improvement in at least two categories in WHO ordinal clinical scale at day 28 or hospital discharge (ClinicalTrials.gov number NCT04494984).<h4>Findings</h4>between August 1st and October 26th, 2020, a total of 245 patients were enrolled. Enrolled patients were assigned to receive two blinded doses of INM005 (<i>n</i> = 118) oEClinicalMedicine100843https://www.ebi.ac.uk/biostudies/studies/S-EPMC8037439biostudies-literatureRBD-specific polyclonal F(ab´)₂ fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial.PMC8037439Luciardi HLVidiella GDobarro MAlzogaray MFColonna MINM005 Study GroupCasas MMAbusamra LMillan SBertetti AStanek VSued OMunoz LLambert STeijeiro RCaruso Dde Miguel BCrudo FNannini EKilstein YIacono MScublinsky DSpatz LCahn PBelloso WHPereiro ASanguineti SZylberman VSolari RCruz PLebersztein GLopardo GCremona ALloret SPGoldbaum FFarina JBarcelona LfalseRBD-specific polyclonal F(ab´)₂ fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial.<h4>Background</h4>passive immunotherapy is a therapeutic alternative for patients with COVID-19. Equine polyclonal antibodies (EpAbs) could represent a source of scalable neutralizing antibodies against SARS-CoV-2.<h4>Methods</h4>we conducted a double-blind, randomized, placebo-controlled trial to assess efficacy and safety of EpAbs (INM005) in hospitalized adult patients with moderate and severe COVID-19 pneumonia in 19 hospitals of Argentina. Primary endpoint was improvement in at least two categories in WHO ordinal clinical scale at day 28 or hospital discharge (ClinicalTrials.gov number NCT04494984).<h4>Findings</h4>between August 1st and October 26th, 2020, a total of 245 patients were enrolled. Enrolled patients were assigned to receive two blinded doses of INM005 (<i>n</i> = 118) o2021-01-01T00:00:00Z2021 Apr2026-04-29T06:29:07.879Z2025-02-19T00:33:49.632ZS-EPMC80374393387014910.1016/j.eclinm.2021.100843